Literature DB >> 23756452

Fentanyl utility function: a risk-benefit composite of pain relief and breathing responses.

Merel Boom1, Erik Olofsen, Meike Neukirchen, René Fussen, Justin Hay, Geert Jan Groeneveld, Leon Aarts, Elise Sarton, Albert Dahan.   

Abstract

INTRODUCTION: Integrating opioid risk and benefit into a single function may give a useful single measure of the opioid's positive and negative effects. An explorative study on the effects of fentanyl on antinociception and respiratory depression was performed to construct fentanyl risk-benefit (utility) functions.
METHODS: Twelve volunteers received a 3.5-μg/kg fentanyl intravenous injection on 2 separate study days. On one occasion, ventilation at a clamped increased carbon dioxide concentration was measured and on another the pain tolerance to electrical stimulation. In both sessions, arterial plasma samples were obtained. The data were analyzed with a population pharmacokinetic-pharmacodynamic model. A simulation study was performed, using the model parameter estimates and their variances, in which simulated subjects received 3.5 μg/kg of fentanyl. The resultant distributions were used to calculate the utility functions, defined as the probability of at least 50% analgesia (an increase in pain tolerance by ≥50%) minus the probability of at least 50% respiratory depression (a reduction in ventilation by ≥50%). Utility functions were constructed in concentration and time domains.
RESULTS: Fentanyl produced significant respiratory depression and analgesia. The pharmacokinetic and pharmacodynamic models adequately described the data. The constructed utility functions were negative at effect-site concentrations of greater than 0.5 ng/ml in the first 90 min after the 3.5 μg/kg bolus infusion.
CONCLUSIONS: Utility functions based on fentanyl's experimental effects on respiration and pain relief were successfully constructed. These functions are useful in multiple effect comparisons among experimental drugs. Further studies are required to assess whether this risk-benefit analysis is valuable in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23756452     DOI: 10.1097/ALN.0b013e31829ce4cb

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  10 in total

1.  μ-Opioid Receptor Agonists: Do They Have Utility in the Treatment of Acute Pain?

Authors:  Thomas K Henthorn; Susan K Mikulich-Gilbertson
Journal:  Anesthesiology       Date:  2018-05       Impact factor: 7.892

2.  Assessing the utility of the utility function.

Authors:  Evan D Kharasch; Carl E Rosow
Journal:  Anesthesiology       Date:  2013-09       Impact factor: 7.892

3.  Bilateral carotid sinus nerve transection exacerbates morphine-induced respiratory depression.

Authors:  Santhosh M Baby; Ryan B Gruber; Alex P Young; Peter M MacFarlane; Luc J Teppema; Stephen J Lewis
Journal:  Eur J Pharmacol       Date:  2018-07-19       Impact factor: 4.432

Review 4.  Laparoscopic surgery: a narrative review of pharmacotherapy in pain management.

Authors:  Sari Sjövall; Merja Kokki; Hannu Kokki
Journal:  Drugs       Date:  2015-11       Impact factor: 9.546

5.  Effects of pain relief on arterial blood o2 saturation.

Authors:  Hossein Alimohammadi; Alireza Baratloo; Ali Abdalvand; Alaleh Rouhipour; Saeed Safari
Journal:  Trauma Mon       Date:  2014-01-25

6.  Modeling buprenorphine reduction of fentanyl-induced respiratory depression.

Authors:  Erik Olofsen; Marijke Hyke Algera; Laurence Moss; Robert L Dobbins; Geert J Groeneveld; Monique van Velzen; Marieke Niesters; Albert Dahan; Celine M Laffont
Journal:  JCI Insight       Date:  2022-05-09

Review 7.  Gastrointestinal pain.

Authors:  Asbjørn M Drewes; Anne E Olesen; Adam D Farmer; Eva Szigethy; Vinciane Rebours; Søren S Olesen
Journal:  Nat Rev Dis Primers       Date:  2020-01-06       Impact factor: 52.329

8.  A Dose-Finding Study of Dexketoprofen in Patients Undergoing Laparoscopic Cholecystectomy: A Randomized Clinical Trial on Effects on the Analgesic Concentration of Oxycodone.

Authors:  Annika Piirainen; Hannu Kokki; Satu Immonen; Matti Eskelinen; Merja R Häkkinen; Heidi Hautajärvi; Merja Kokki
Journal:  Drugs R D       Date:  2015-12

9.  Bifunctional peptide-based opioid agonist/nociceptin antagonist ligand for dual treatment of nociceptive and neuropathic pain.

Authors:  Camille Lagard; Lucie Chevillard; Karel Guillemyn; Patricia Risède; Jean-Louis Laplanche; Mariana Spetea; Steven Ballet; Bruno Mégarbane
Journal:  Pain       Date:  2017-03       Impact factor: 7.926

10.  Tolerance to Opioid-Induced Respiratory Depression in Chronic High-Dose Opioid Users: A Model-Based Comparison With Opioid-Naïve Individuals.

Authors:  Marijke Hyke Algera; Erik Olofsen; Laurence Moss; Robert L Dobbins; Marieke Niesters; Monique van Velzen; Geert Jan Groeneveld; Jules Heuberger; Celine M Laffont; Albert Dahan
Journal:  Clin Pharmacol Ther       Date:  2020-10-05       Impact factor: 6.875

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.